1. Use of the Cumulative Proportion of Responders Analysis Graph to Present Pain Data Over a Range of Cut-Off Points: Making Clinical Trial Data More Understandable 
John T. Farrar, MD, PhD, Robert H. Dworkin, PhD, Mitchell B. Max, MD 
Journal of Pain and Symptom Management 
Volume 31, Issue 4, Pages (April 2006)
DOI: /j.jpainsymman
Copyright © 2006 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1
A CPRA graph created with percent change in 0–10 NRS pain intensity data from a randomized, double-blind clinical trial of patients with cancer-related breakthrough pain treated with OTFC vs. placebo.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2006 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2
A CPRA graph created with percent change in 0–10 NRS pain intensity data from a randomized, double-blind clinical trial of patients with cancer-related breakthrough pain treated with OTFC vs. MSIR.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2006 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
A CPRA graph created with percent change in 0–10 NRS pain intensity data from a randomized, double-blind clinical trial of patients with postherpetic neuralgia treated with an oral dose of 600mg/day of pregabalin vs. placebo (300mg/day was administered to patients with creatinine clearances of less than 30 to achieve a similar concentration of pregabalin as the 600mg group).
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2006 U.S. Cancer Pain Relief Committee Terms and Conditions

5. Fig. 4
A CPRA graph created with Gracely scale pain intensity difference data between week 1 and week 6 from a randomized, double-blind clinical trial of patients with diabetic neuropathic pain treated with amitriptyline, desipramine, fluoxetine, or placebo.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2006 U.S. Cancer Pain Relief Committee Terms and Conditions

6. Fig. 5
A CPRA graph created with the global change score between week 1 and week 6 for all groups from a randomized, double-blind clinical trial of patients with diabetic neuropathic pain treated with amitriptyline, desipramine, fluoxetine, or placebo.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2006 U.S. Cancer Pain Relief Committee Terms and Conditions